drugset / Trial / NCT05198505
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
Phase 1
Unknown
280 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more effectively improve the effect of inhibiting tumor occurrence and development.
Timeline
- Start
- 2022-04-27
- Primary completion
- 2023-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2868 | Protein / enzyme biologic | 1.5 mg | — |
| Subject | TQB2868 | Protein / enzyme biologic | 600 mg | — |